ATRA

Atara Biotherapeutics, Inc.

11.41 USD
+0.40 (+3.59%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Atara Biotherapeutics, Inc. stock is up 28.15% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 July’s closed higher than June.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.